ScripThe future direction for PureTech Health is again under the spotlight as a week after its chair stepped down, the company is now looking for a new CEO following the departure of Bharatt Chowrira. The
ScripLess than two months after saying that it would wind down its business of stem cell-based therapies for blood cancers, Vor Bio of the US has bounced back, rebranding as an autoimmune disease company a
ScripPureTech’s idiopathic pulmonary fibrosis (IPF) candidate, deupirfenidone, is ready to enter a pivotal study after showing improved efficacy compared with standard treatment in a Phase II study. The pr
ScripIt looks as though nothing will come of the takeover talks PureTech Health has held with Nordic Capital Epsilon but there is a compelling argument for taking its ‘hub-and-spoke’ business private in th